You are here

Article Text

Article menu
Download PDFPDF
Letter
Short-term effect of intravitreal anti-VEGFs delivery on intraocular pressure
  1. S Nabili1,
  2. M Stevenson2,
  3. U Chakravarty1,3,
  4. T Moutray1
  1. 1
    Directorate of Ophthalmology, Head and Skeletal Division, Royal Victoria Hospital Belfast, Belfast, UK
  2. 2
    Centre for Population Sciences, The Queen’s University of Belfast, Belfast, UK
  3. 3
    Centre for Vision Sciences, The Queen’s University of Belfast, Belfast, UK
  1. Dr T Moutray, Department of Ophthalmology, Royal Victoria Hospital, Belfast, UK; tanya.moutray{at}btopenworld.com

https://doi.org/10.1136/bjo.2008.151191

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Since the successful introduction of antivascular endothelial growth factor (VEGF) intravitreal injections (IVT) for the management of age-related macular degeneration (AMD), this treatment has gained popularity. Several studies have reported on the complications of anti-VEGF IVT, including a transient rise in intraocular pressure (IOP).1

    We aimed to determine whether IOP measurement post-IVT is necessary following injection of the commonly used anti-VEGF agents: ranibizumab (Lucentis), bevacizumab (Avastin) and pegabtanib (Macugen).

    METHOD

    This was a retrospective observational study of postinjection change in IOP in patients with neovascular AMD who received an injection of an anti-VEGF drug between September 2006 and March 2008. Patients were treated with one of three anti-VEGF drugs (ranibizumab 0.5 mg, bevacizumab 1.25 mg, pegabtanib 0.3 mg) using a sterile technique. Povidine iodine 5% preparation and topical oxybuprocaine anaesthetic …

    View Full Text

    Footnotes

    • Competing interests: None.